Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 76K adjuvant nivolumab versus placebo after resection of stage IIB/C melanoma
2022-502354-14-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Nivolumab with Placebo (2 arms). Primary endpoint: RFS. Planned start Oct 2019; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2022-502354-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502354-14-00.